• Fibrocell, Castle Creek Enter Collaboration contractpharma
    April 16, 2019
    To develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)...
PharmaSources Customer Service